“(FDA) has granted orphan drug designation for Idera Pharmaceuticals' IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, to treat diffuse large B-cell lymphoma (DLBCL). Currently, the company is conducting a clinical trial of IMO-8400 in patients with relapsed or refra
1
Regulation Archives - Pharmaceutical Business review
